Avadel Pharmaceuticals — Flamel Technologies — Q3 2016 Earnings Presentation
18 slides from Avadel Pharmaceuticals's earnings presentation, Nov 7, 2016
Slide 1: Third Quarter 2016 Earnings Conference Call
November 7, 2016 Third Quarter 2016 Earnings Conference Call 1 Third Quarter 2016 Earnings Conference Call
Slide 2: Forward Looking Statements
November 7, 2016 Third Quarter 2016 Earnings Conference Call 2 Forward Looking Statements This presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward
Slide 3: Call Outline
November 7, 2016 Third Quarter 2016 Earnings Conference Call 3 Call Outline Phase III Trial Initiation – REST-ON Sodium Oxybate Patent Landscape Base Business Overview Akovaz™ Bloxiverz® Vazculep® Business Development Status Cross-Border Merger & Name Change Overview of Income Stat
Slide 4: REST-ON Phase III Trial
November 7, 2016 Third Quarter 2016 Earnings Conference Call 4 REST-ON Phase III Trial Initiation of Phase III Pivotal Trial (REST-ON) announced (Sept 26th) Special Protocol Assessment process completed (Oct 6th) Sites in Canada and Germany have started screening and enrollment Expect to dos
Slide 5: Sodium Oxybate IP Landscape
November 7, 2016 Third Quarter 2016 Earnings Conference Call 5 Sodium Oxybate IP Landscape JAZZ – 6 of 7 REMS patents overturned by PTAB Settled with Wockhardt & Ranbaxy for 2026 generic entry Yet to settle with other filers – including first to file, Roxane (Hikma) ‘306 patent for concomita
Slide 6: Base Business
November 7, 2016 Third Quarter 2016 Earnings Conference Call 6 Base Business • Akovaz launched Aug 2016 • $5.6 million in revenues 3Q 2016 • On target to exit 2016 with 20-30% market share • Averaged 40% neostigmine market during 3Q 2016 • $15.6 million in revenues 3Q 2016 • Smaller overall market v
Slide 7: Business Development
November 7, 2016 Third Quarter 2016 Earnings Conference Call 7 Business Development 4th Unapproved Marketed Drug identified – awaiting feedback from FDA on potential clinical work Looking to grow inorganically – searching for accretive commercial stage products to fold into FSC Actively seekin
Slide 8: Coming soon… Avadel Pharmaceuticals plc
November 7, 2016 Third Quarter 2016 Earnings Conference Call 8 Coming soon… Avadel Pharmaceuticals plc (NASDAQ: AVDL) “AdVAnced DELivery” Cross-border merger from France to Ireland effective January 1, 2017 No changes to capital structure or share count COMPANY WILL CONTINUE TO OPERATE AS FL
Slide 9: GAAP Financial Results
November 7, 2016 Third Quarter 2016 Earnings Conference Call 9 GAAP Financial Results (in $000s) Q3 2016 Q2 2016 Q3 2015 Q3 2016 vs. Q2 2016 Q3 2016 vs. Q3 2015 Revenue 32,087$ 38,858$ 47,313$ (6,771)$ (15,226)$ Cost of products and services sold 2,844 3,907 2,087 (1,063) 757 Research and developmen
Slide 10: Non-GAAP Financial Results
November 7, 2016 Third Quarter 2016 Earnings Conference Call 10 Non-GAAP Financial Results (in $000s) Q3 2016 Q2 2016 Q3 2015 Q3 2016 vs. Q2 2016 Q3 2016 vs. Q3 2015 Revenue 32,087$ 38,858$ 47,313$ (6,771)$ (15,226)$ Cost of products and services sold 2,844 3,145 2,087 (301) 757 Research and develop
Slide 11: Revenue by product
November 7, 2016 Third Quarter 2016 Earnings Conference Call 11 (in $000s) Q3 2016 Q2 2016 Q3 2015 Q3 2016 vs. Q2 2016 Q3 2016 vs. Q3 2015 Bloxiverz 15,591$ 25,620$ 41,243$ (10,029)$ (25,652)$ Vazculep 9,340 10,421 5,605 (1,081) 3,735 Akovaz 5,568 - - 5,568 5,568 Other 841 2,124 465 (1,283) 376 Tota
Slide 12: Cash Flow Summary
November 7, 2016 Third Quarter 2016 Earnings Conference Call 12 Cash Flow Summary (in $000s) 2016 2015 TOTAL Cash and Marketable Securities Beginning Balance 144,802$ 92,834$ Operating Cash Flows (excluding tax and earnout/royalty payments) 47,154 92,377 Tax Payments (22,200) (34,382) Earnout/Royalt
Slide 13: Full-Year 2016 Guidance
November 7, 2016 Third Quarter 2016 Earnings Conference Call 13 Full-Year 2016 Guidance Current PREVIOUS Revenue $133M - $143M $125M - $140M Research & Development Expenses $30M - $40M $30M - $40M
Slide 14: Question & Answer
November 7, 2016 Third Quarter 2016 Earnings Conference Call 14 Question & Answer
Slide 15: Appendix
November 7, 2016 Third Quarter 2016 Earnings Conference Call 15 Appendix
Slide 16: GAAP to Non-GAAP Reconciliations: Three Months Ended September 30, 2016
November 7, 2016 Third Quarter 2016 Earnings Conference Call 16 GAAP to Non-GAAP Reconciliations Three Months Ended September 30, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value remeasurements Contingent
Slide 17: GAAP to Non-GAAP Reconciliations: Three Months Ended June 30, 2016
November 7, 2016 Third Quarter 2016 Earnings Conference Call 17 GAAP to Non-GAAP Reconciliations Three Months Ended June 30, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Purchase accounting adjustments - FSC Contingent related party payable fair
Slide 18: GAAP to Non-GAAP Reconciliations: Three Months Ended September 30, 2015
November 7, 2016 Third Quarter 2016 Earnings Conference Call 18 GAAP to Non-GAAP Reconciliations Three Months Ended September 30, 2015: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value remeasurements Contingent